PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1111183
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1111183
The glioblastoma multiforme treatment market is projected to register a substantial CAGR of 8.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
North America Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Israel, UAE, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Increasing prevalence of the disease
High incidence in emerging markets.
F. Hoffmann-La Roche AG
Amgen Inc.
Merck & Co., Inc.
Pfizer Inc.
Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare)
ZEISS International
Amneal Pharmaceuticals LLC
Elekta
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd.
Eckert & Ziegler
Accord Healthcare
Angiochem
ANI Pharmaceuticals, Inc.
Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.)
AstraZeneca
Cantex Pharmaceuticals, Inc.
CELON LABS
Diffusion Pharmaceuticals Inc.
EnGeneIC
ERC.SA.
Genenta science
Jazz Pharmaceuticals, Inc.
Loxo Oncology (A Subsidiary of Eli Lilly)
Novartis AG
VBL THERAPEUTICS
Viatris Inc.
Zydus Pharmaceuticals, Inc.,